Patients with systemic lupus erythematosus have an increased incidence of atherosclerosis, thrombosis, and thromboembolic disease."1 Some studies have linked this increased incidence of vascular disease in lupus with the expression of antiphospholipid antibodiesnotably, anticardiolipin antibodies.l'0
The close correlation between the presence of antiphospholipid antibodies and the lupus anticoagulant suggests that these antibodies may play a direct part in the pathogenesis of vascular disease. " 12 Antiphospholipid antibodies act at several sites in the coagulation cascade with an overall effect in vivo of promoting thrombosis. The enhancing effect of phospholipid on the endothelial cell cofactor thrombomodulin is neutralised by antiphospholipid antibodies. As a result, protein C activation on the surface of endothelial cells is inhibited, promoting thrombosis and suppressing fibrinolysis.'3 IgG antiphospholipid antibodies interfere with cell surface prostacyclin formation and lead to platelet aggregation.
" Direct damage to endothelial cells is also recognised. '5 Hyperlipidaemia is a recognised risk factor for vascular disease in lupus. '6 17 The importance of hyperlipidaemia in the pathogenesis of atherosclerosis has been firmly established. ' ApoproteinB(mg/l) t 2-961 (2-882 to 3 040) 12 patients. Table 3 lists these episodes, including arterial and venous thrombotic and thromboembolic disorders. The average age of the patients with vascular disease was 44 5 years compared with 39-2 in the unaffected lupus patients. This difference was not statistically significant. Ten of the 13 patients with vascular disease had been treated with steroids, four at doses greater than 10 mg/day for six months before testing, suggesting that the disease had been more active than in those without a history of vascular complications.
CORRELATIONS WITH VASCULAR DISEASE
Raised anticardiolipin antibodies were detected in eight of the 13 patients with vascular disease. One expressed IgM alone, three expressed both IgG and IgM, and four expressed IgG alone. Of the 48 remaining patients with no vascular disease in whom anticardiolipin antibodies were assayed, detectable antibody levels were found in 14. The higher prevalence of anticardiolipin antibodies among the patients with vascular disease was not statistically significant at the p<0 05 level.
No significant difference was noted in fasting lipid and apoprotein concentrations when patients with and without vascular complications were compared.
Of the patients in the upper third of the 
